Back to search results
NCT04545736

Oral Metformin for Treatment of ABCA4 Retinopathy

Active, Not Recruiting
PHASE1Ages 12+InterventionalTreatment
National Eye Institute (NEI)
~55 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:Metformin hydrochloride

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The difference in growth rate of square-root transformed area of EZ band loss (vAreaEZloss)
Measured over Pre-treatment, Baseline, Month 24

Conditions

ABCA4 Retinopathy
Stargardt Disease
Retinal Dystrophy
Retinal Degeneration

Explore related trials

ABCA4 RetinopathyStargardt DiseaseRetinal-Specific Phospholipid-Transporting ATPase ABCA4

Where it's being run

2 sites across 2 states
Maryland1
Michigan1

Study leadership

  • Brian P Brooks, M.D. · PRINCIPAL_INVESTIGATOR · National Eye Institute (NEI)

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have had a surgical sterilization OR
Completely abstain from intercourse OR
Practice at least one form of contraception while actively taking IP on the study and at least one week after IP discontinuation OR
Have a partner who had a surgical sterilization OR
Have a partner who practices one form of contraception while the female participant is actively taking IP and at least one week after the female participant discontinues IP.
Have had a surgical sterilization OR
Completely abstain from intercourse OR
Practice at least one form of contraception while actively taking IP on the study and at least for 3 months after IP discontinuation OR
Have a partner who had a surgical sterilization OR
Have a partner who practices one form of contraception while the male participant actively takes IP and at least 3 months after the male participant discontinues IP.

What this trial measures

  • The difference in growth rate of square-root transformed area of EZ band loss (vAreaEZloss)Pre-treatment, Baseline, Month 24

    The difference in growth rate of vAreaEZloss, from OCT, between the pre-treatment phase and treatment phase.